More recently, the combination of HAIC with systemic therapy, such as lenvatinib and programmed cell death protein-1 (PD-1), has been suggested to significantly improve the prognosis of advanced HCC [11–13]. This evidence concerns the gene PDCD1 and hepatocellular carcinoma.